MeiraGTx Holdings Past Earnings Performance
Past criteria checks 0/6
MeiraGTx Holdings's earnings have been declining at an average annual rate of -14.1%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 2.7% per year.
Key information
-14.1%
Earnings growth rate
-1.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 2.7% |
| Return on equity | -116.4% |
| Net Margin | -1,146.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts
Jul 15MeiraGTx Holdings (NASDAQ:MGTX) Has Debt But No Earnings; Should You Worry?
Jun 19
MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met
Feb 15Does MeiraGTx Holdings (NASDAQ:MGTX) Have A Healthy Balance Sheet?
Sep 08Calculating The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX)
Apr 11MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Reducing Their Forecasts For This Year
Mar 16MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are More Bearish Than They Used To Be
Nov 16MeiraGTx GAAP EPS of -$0.76, revenue of $10.76M
Aug 11MeiraGTx inks $100M debt agreement backed by manufacturing facilities
Aug 03MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans
Apr 29Analysts' Revenue Estimates For MeiraGTx Holdings plc (NASDAQ:MGTX) Are Surging Higher
Mar 15MeiraGTx: Perceptive's Large Stake Makes It Interesting
Jan 19MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans
Dec 28Revenue & Expenses Breakdown
How MeiraGTx Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 8 | -93 | 47 | 131 |
| 31 Mar 24 | 11 | -74 | 48 | 116 |
| 31 Dec 23 | 14 | -84 | 47 | 104 |
| 30 Sep 23 | 7 | -132 | 49 | 92 |
| 30 Jun 23 | 6 | -125 | 50 | 81 |
| 31 Mar 23 | 14 | -129 | 48 | 85 |
| 31 Dec 22 | 16 | -130 | 47 | 86 |
| 30 Sep 22 | 42 | -112 | 48 | 77 |
| 30 Jun 22 | 44 | -101 | 45 | 82 |
| 31 Mar 22 | 39 | -87 | 45 | 73 |
| 31 Dec 21 | 38 | -80 | 44 | 67 |
| 30 Sep 21 | 20 | -80 | 40 | 59 |
| 30 Jun 21 | 19 | -61 | 41 | 42 |
| 31 Mar 21 | 16 | -66 | 42 | 43 |
| 31 Dec 20 | 16 | -58 | 44 | 34 |
| 30 Sep 20 | 19 | -53 | 47 | 26 |
| 30 Jun 20 | 17 | -57 | 48 | 26 |
| 31 Mar 20 | 17 | -52 | 50 | 20 |
| 31 Dec 19 | 13 | -55 | 47 | 25 |
| 30 Sep 19 | 6 | -70 | 41 | 38 |
| 30 Jun 19 | 3 | -75 | 38 | 42 |
| 31 Mar 19 | 1 | -86 | 42 | 40 |
| 31 Dec 18 | 0 | -85 | 44 | 34 |
| 30 Sep 18 | 0 | -73 | 38 | 29 |
| 30 Jun 18 | 0 | -66 | 33 | 27 |
| 31 Mar 18 | 0 | -42 | 18 | 24 |
| 31 Dec 17 | 0 | -32 | 9 | 22 |
Quality Earnings: MGTX is currently unprofitable.
Growing Profit Margin: MGTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MGTX is unprofitable, and losses have increased over the past 5 years at a rate of 14.1% per year.
Accelerating Growth: Unable to compare MGTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MGTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: MGTX has a negative Return on Equity (-116.37%), as it is currently unprofitable.